AlphaMark Advisors LLC Takes Position in HealthEquity, Inc. (NASDAQ:HQY)

AlphaMark Advisors LLC acquired a new position in HealthEquity, Inc. (NASDAQ:HQY) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 4,592 shares of the company’s stock, valued at approximately $375,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HQY. Xponance Inc. boosted its holdings in HealthEquity by 1.2% during the fourth quarter. Xponance Inc. now owns 12,269 shares of the company’s stock worth $813,000 after buying an additional 147 shares in the last quarter. KLR Investment Advisors LLC grew its holdings in shares of HealthEquity by 4.2% in the 4th quarter. KLR Investment Advisors LLC now owns 5,914 shares of the company’s stock worth $392,000 after acquiring an additional 241 shares during the last quarter. Capstone Investment Advisors LLC raised its position in shares of HealthEquity by 7.0% during the fourth quarter. Capstone Investment Advisors LLC now owns 3,710 shares of the company’s stock worth $246,000 after purchasing an additional 243 shares during the period. Campbell & CO Investment Adviser LLC lifted its holdings in shares of HealthEquity by 3.2% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,195 shares of the company’s stock valued at $543,000 after purchasing an additional 254 shares during the last quarter. Finally, Mariner LLC boosted its position in shares of HealthEquity by 2.4% in the 3rd quarter. Mariner LLC now owns 14,983 shares of the company’s stock valued at $1,095,000 after purchasing an additional 345 shares during the period. Institutional investors own 99.55% of the company’s stock.

Insiders Place Their Bets

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of HealthEquity stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total transaction of $34,000.00. Following the completion of the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at $7,693,775. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total value of $34,000.00. Following the transaction, the insider now owns 90,515 shares of the company’s stock, valued at $7,693,775. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jon Kessler sold 32,326 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $82.83, for a total transaction of $2,677,562.58. Following the completion of the sale, the chief executive officer now owns 232,176 shares of the company’s stock, valued at approximately $19,231,138.08. The disclosure for this sale can be found here. Insiders sold a total of 34,806 shares of company stock worth $2,888,383 over the last quarter. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HQY. Robert W. Baird boosted their price objective on HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. Raymond James boosted their price target on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a research report on Tuesday, June 4th. KeyCorp increased their target price on HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Finally, Barrington Research raised their target price on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, HealthEquity presently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

HealthEquity Stock Performance

HealthEquity stock traded up $0.42 during trading hours on Monday, hitting $86.62. The stock had a trading volume of 658,987 shares, compared to its average volume of 608,539. The company has a 50-day moving average of $81.14 and a two-hundred day moving average of $78.32. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.44. HealthEquity, Inc. has a fifty-two week low of $61.32 and a fifty-two week high of $88.26. The company has a market cap of $7.54 billion, a PE ratio of 94.15, a price-to-earnings-growth ratio of 1.45 and a beta of 0.55.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Monday, June 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.08. HealthEquity had a net margin of 7.71% and a return on equity of 7.77%. The firm had revenue of $287.60 million for the quarter, compared to analyst estimates of $278.78 million. On average, equities research analysts anticipate that HealthEquity, Inc. will post 2.12 EPS for the current fiscal year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.